SGMT

$5.19

Market ClosedAs of Mar 17, 8:00 PM UTC

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$5.19
Potential Upside
5%
Whystock Fair Value$5.45
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$169.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-38.20%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
22.18

Recent News

MarketBeat
Mar 1, 2026

Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.

Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy around fatty acid synthase (FASN) inhibition, with development efforts centered on metabolic dysfunction-associated steatohepatitis (MASH), acne, and

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Feb 15, 2026

Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference

Sagimet Biosciences (NASDAQ:SGMT) used a presentation at Guggenheim’s Emerging Outlook Conference to highlight its strategy of targeting fatty acid synthase (FASN) across metabolic and dermatologic indications, and to outline upcoming clinical milestones and cash runway. Focus on FASN inhibition ac

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Feb 5, 2026

A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial Success

Sagimet Biosciences (SGMT) drew fresh attention after reporting that Denifanstat met all primary and secondary endpoints with a favorable safety profile in a Phase 3 acne trial, underscoring progress for its FASN inhibitor approach. See our latest analysis for Sagimet Biosciences. The latest Denifanstat acne data arrives after a mixed stretch for the stock, with a 9.75% 1 month share price return and a 20.94% decline over 3 months, yet a 1 year total shareholder return of 18.52%. This hints...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Barrons.com
Feb 3, 2026

After Clearing Up Acne, Sagimet Stock Rises

Shares of Sagimet Biosciences were up as much as 12% after encouraging clinical trial results for its acne treatment.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Fly
Feb 3, 2026

Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls

Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.